mk-2-in-3

MK2-IN-3 (MK2 Inhibitor III) 是选择性的 MAPKAP-K2 (MK-2)抑制剂(IC50:8.5 nM)，能够抑制 U937 细胞及体内 TNFα 的生成。

MK2-IN-3 hydrate (MK-2 Inhibitor III) 是一种口服有活性的、ATP 竞争性的MAPKAP-K2 (MK-2)选择性抑制剂(IC50:0.85 nM)。

Ascr#2 (asc-C6-MK)是秀丽隐杆线虫中的糖苷类化合物，促进 dauer 形成。Ascr#2 在低浓度下与 ascr#3 的混合物可作为雄性引诱剂，可用于检测种群密度。

Reveromycin A is the major component of a complex of spiroketal antibiotics isolated from Streptomyces sp. It inhibits the mitogenic activity of epidermal growth factor in Balb MK cells (IC50 = 0.7 μg ml), displays antiproliferative activity against human KB and K562 tumor cell lines (IC50s = 1.9 and 1.6 μg ml, respectively), and demonstrates antifungal activity against C. albicans (MIC = 2 μg ml at pH 3). Reveromycin A also has been shown to inhibit bone resorption by inducing apoptosis in osteoclasts with an IC50 value of 0.7 μM.

Reveromycin D is a bacterial metabolite originally isolated from Streptomyces. It inhibits EGF-induced mitogenic activity in Balb MK cells and has pH-dependent antifungal activity against C. albicans (MICs = 2 and >500 μg ml at pH 3 and 7.4, respectively). Reveromycin D also inhibits proliferation of KB and K562 cells (IC50s = 1.6 and 1.3 μg ml, respectively).

Dalotuzumab (MK-0646) 是一种重组人源化IgG1单克隆抗体，特异性靶向胰岛素样生长因子1受体（IGF-1R）。其作用机制涉及抑制IGF介导的致癌信号传导，从而诱导肿瘤细胞凋亡和细胞周期停滞，并且在与其它化疗药物联合使用时展现出增强的抗肿瘤疗效。

Favezelimab (MK-4280) 是一种人源化单克隆抗体，靶向 LAG-3，通过抑制 LAG-3 与其配体 MHC II 的分子相互作用，恢复 T 细胞功能，Favezelimab 尤其用于与 PD-L1 抑制剂 Pembrolizumab (HY-P9902) 联合应用的协同作用的研究。